Annie Yoshiyama
Fortune : 270 202 $ au 31/05/2026
Fortune : 270 202 $ au 31/05/2026
Annie Yoshiyama currently works at Allogene Therapeutics, Inc., as Senior Vice President & Controller from 2024.
Ms. Yoshiyama also formerly worked at Tricida, Inc., as Chief Accounting Officer & Vice President-Finance, Dolby Laboratories, Inc., as Senior Financial Reporting from 2008 to 2018, and AN2 Therapeutics, Inc., as Vice President-Finance & Controller from 2023 to 2024.
Ms. Yoshiyama received her undergraduate degree and graduate degree from the University of Southern California.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 21/04/2026 | 124 517 ( 0,04 % ) | 270 202 $ | 31/05/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| ALLOGENE THERAPEUTICS, INC. | Comptroller/Controller/Auditor | 05/06/2024 |
| Sociétés | Poste | Fin |
|---|---|---|
| AN2 THERAPEUTICS, INC. | Comptroller/Controller/Auditor | 01/03/2024 |
| TRICIDA, INC. | Comptroller/Controller/Auditor | 01/09/2023 |
| DOLBY LABORATORIES, INC. | Corporate Officer/Principal | 01/06/2018 |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 5 |
|---|---|
Tricida, Inc.
Tricida, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical preparation products | Health Technology |
University of Southern California
University of Southern California Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Dolby Laboratories, Inc.
Dolby Laboratories, Inc. Packaged SoftwareTechnology Services Develops audio and imaging technologies and products for cinema, television, broadcast & entertainment industries | Technology Services |
Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage immuno-oncology | Health Technology |
AN2 Therapeutics, Inc.
AN2 Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national